CD3EAP interacts with nuclear factor-kappa-B (NFKB1) and cellular tumor antigen p53 (TP53) proteins and is associated with ‘poor’ outcome for multiple myeloma patients [55]. Here, TP53 is linked to plasma cell myeloma.